Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting Nov 15, 2020 10:00am EST
Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020) Nov 12, 2020 8:30am EST
Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress Nov 09, 2020 4:01pm EST
Atara Biotherapeutics to Announce Third Quarter 2020 Financial Results on Monday, November 9, 2020 Nov 02, 2020 4:01pm EST
Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Access Program in e-Poster at ESMO 2020 Virtual Congress Sep 14, 2020 8:30am EDT
Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188 Sep 11, 2020 8:00am EDT
Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors Sep 08, 2020 7:00am EDT
Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive Multiple Sclerosis at MSVirtual2020 Sep 01, 2020 7:00am EDT
Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress Aug 05, 2020 4:01pm EDT
